Healthcare Industry News: Sanofi-aventis
News Release - April 24, 2007
Roxane Laboratories, Inc. Announces Launch of Zolpidem Tartrate Tablets CIV, 5mg and 10mgCOLUMBUS, Ohio, April 24 (HSMN NewsFeed) -- Roxane Laboratories, Inc. today announced the launch of Zolpidem Tartrate Tablets CIV, 5mg and 10mg. The product will be available in bottles of 100 and 500, as well as a 100 count Unit Dose package.
Roxane Laboratories' Zolpidem Tartrate Tablets CIV, 5 mg and 10mg are AB rated to AMBIENŽ (zolpidem tartrate) Tablets CIV, 5 mg and 10mg. Zolpidem Tartrate Tablets CIV had total annual sales of approximately $2.1 Billion, based on IMS sales data for the twelve months ending December 2006.
Full prescribing information for Zolpidem Tartrate Tablets CIV, 5mg and 10mg is available on the Roxane web site at www.Roxane.com or upon request by calling Roxane Laboratories Technical Product Information at 1-800-962-8364.
Roxane Laboratories, Inc. (Columbus, Ohio), is a subsidiary of Boehringer Ingelheim Corporation, based in Ridgefield, CT and a member of the Boehringer Ingelheim group of companies.
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 137 affiliates in 47 countries and approximately 38,400 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2006, Boehringer Ingelheim posted net sales of US $13.3 billion (10.6 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.
For more information, please visit http://us.boehringer-ingelheim.com.
AMBIENŽ is a registered trademark of Sanofi-aventis
Source: Roxane Laboratories
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.